Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

Der Internist·2018
Same author

[Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

Der Anaesthesist·2018
Same author

Diagnosis and treatment of superficial vein thrombosis.

Hamostaseologie·2013
Same author

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Journal of thrombosis and haemostasis : JTH·2012
Same author

International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer.

Journal of thrombosis and haemostasis : JTH·2012
Same author

[New oral anticoagulants and chronic kidney disease].

Der Internist·2012

Related Experiment Video

Updated: Jul 7, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

[New anticoagulants].

R M Bauersachs1

  • 1Medizinische Klinik IV - Max Ratschow Klinik für Angiologie, Klinikum Darmstadt, Heidelberger Landstr. 379, 64297 Darmstadt. Rupert.Bauersachs@Klinikum-Darmstadt.de

Hamostaseologie
|February 19, 2008
PubMed
Summary

New anticoagulants targeting factor Xa and thrombin show promise for preventing venous thromboembolism (VTE). Several direct factor Xa inhibitors are in late-stage trials, with some already approved for VTE prevention.

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiology

Background:

  • Anticoagulant therapy is crucial for managing thromboembolic disorders.
  • Traditional anticoagulants have limitations, necessitating the development of novel agents.
  • The coagulation cascade presents multiple targets for anticoagulant drug development.

Purpose of the Study:

  • To review the latest advancements in new anticoagulant drugs.
  • To highlight novel targets within the coagulation pathway, including factor Xa and thrombin inhibition.
  • To focus on anticoagulants in late-stage development for venous thromboembolism (VTE) prevention.

Main Methods:

  • Review of current literature and clinical trial data.
  • Analysis of anticoagulants targeting coagulation initiation, factor Xa, and thrombin.

Related Experiment Videos

Last Updated: Jul 7, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

  • Focus on agents that have completed Phase II trials for VTE prevention.

    • Main Results:

    • Fondaparinux, an indirect factor Xa inhibitor, is approved for VTE prevention and treatment.
    • Rivaroxaban is the first approved direct factor Xa inhibitor for VTE prevention, with ongoing trials for other indications.
    • Apixaban and Dabigatran are other promising direct factor Xa and thrombin inhibitors, respectively, in late-stage clinical development.

    Conclusions:

    • New anticoagulants, particularly factor Xa and direct thrombin inhibitors, offer significant potential in VTE prevention and treatment.
    • Several agents are progressing through late-stage clinical trials, indicating a shift in anticoagulant therapy.
    • Ongoing research and development are crucial for optimizing the use of these novel anticoagulants.